Cited by 280Iron Metabolism and DisordersBreast Cancer Treatment StudiesFerroptosis and cancer prognosis

Transferrin and transferrin receptors in carcinoma of the breast

Page Faulk, W., Hsi, Bae-Li, Stevens, P.J.·1980·The Lancet

Abstract

Breast tissues from 59 patients were immunohistologically studied for transferrin and transferrin receptors. None of the 8 normal breasts or 22 benign mastopathies, and only 1 of 7 fibroadenomas were reactive for transferrin, but 16 (72.7%) of 22 carcinomas were positive and parallel sections showed histopathologically that the rective areas were confined to tumour-cell membranes. That breast-tumour transferrin is probably receptor-bound in vivo was indicatd by its complete chemical removal in vitro and return to the same cells following reincubation with dilute solutions of transferrin. Similar bindig is found on certain normal or transformed cells and at the maternofetal interface of human placentae. It is suggested that this oncofetal receptor preferentially binds apotransferrin and may offer a novel approach to more specific therapy of certain breast cancers.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(80)90440-7

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Upregulation of the Tf/TfR iron acquisition pathway is found in a variety of cancers, including breast and colon.

    “Upregulation of this highly conserved iron acquisition pathway is found in a variety of cancers, including breast and colon [90,91,92,93].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Page Faulk, W., Hsi, B.-L., & Stevens, P. J.
Affiliations
Queen Victoria Hospital (GB)
Venue
The Lancet
Publisher
Elsevier BV
Published
1980-08
Volume
316
Issue
8191
Pages
390-392
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2079229575
Cited by
280
References
18
Citations by year
2026: 2 · 2025: 8 · 2024: 2 · 2023: 6 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 8 · 2018: 5 · 2017: 8 · 2015: 3 · 2014: 8 · 2013: 6 · 2012: 8
FWCI
8.97
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
Keywords
transferrin, transferrin receptor, breast cancer, apotransferrin, oncofetal protein, tumor cell membrane, fibroadenoma, benign breast disease, breast cancer treatment
MeSH terms
Breast, Breast Neoplasms, Cell Membrane, Female, Fetal Proteins, Fluorescent Antibody Technique, Humans, Receptors, Cell Surface, Transferrin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review